The Ginkgo biloba extract (GbE) is a commercial product used as a nutraceutic herbal remedy in Europe and US. It contains 27% of the polyphenols isorhamnetin, kaempferol, and quercetin, as antioxidants. We used male adult Wistar rats (200–300 g), divided into four groups: control group (treated with 5.0 mg/kg of sodium chloride, intravenous), titanium dioxide nanoparticles (TiO2-NPs) group (5.0 mg/kg, intravenous), GbE group (10 mg/kg, intraperitoneal), and GbE + TiO2-NPs group (treated 24 h before with 10 mg/kg of GbE, intraperitoneal), followed, 24 h later, by 5.0 mg/kg of TiO2-NPs intravenously. The statistical analysis was performed using Student’s t-test for grouped data with ANOVA posttest. The GbE protected renal cells against the effects of TiO2-NPs because it reversed the increased activity of γ-glutamyltranspeptidase and the enzymatic activity of dipeptidylaminopeptidase IV at all times tested (0–5, 5–24, 24–48, and 48–72 h). Also it reversed the glucosuria, hypernatriuria, and urine osmolarity at three times tested (5–24, 24–48, and 48–72). Thus, we conclude that GbE has a beneficial activity in the cytoplasmic membranes of brush border cells on the renal tubules, against the adverse effects that can be produced by some xenobiotics in this case the TiO2-NPs, in experimental rats.
1. Introduction
The main function of kidneys, in mammals, is the excretion of metabolic end products from the body and the regulation of extracellular fluid volume and electrolyte composition [1]. Their high blood flow, combined with their ability to concentrate solutes, exposes them to high concentration of xenobiotics present in the systemic circulation. Because of the rich blood supply of the kidneys, in relation to their mass, this organ is particularly liable to damage by toxic substances.
Most living organisms are exposed to nanoparticles (NPs) through the gastrointestinal tract, the lungs, and the skin [2–4]. Moreover, titanium dioxide nanoparticles (TiO2-NPs) affect kidney cells in vitro [5–7] and in vivo [8].
Once into the body, the NPs can interact with cell structures like the plasmatic membrane and cause disruption of it. Some of the biological effects of TiO2-NPs in nanomedicine, after intravenous injection, deliver TiO2-NPs into the human body: they induce pathological lesions in liver, spleen, kidneys, and brain [9]. Also, the intravenous administration of TiO2-NPs (5 mg/kg) in rats causes an accumulation of nanoparticles in the kidneys with the highest burden on a day 1 after exposure and remains until day 14 [10]. Furthermore, after a single oral administration (5 g/kg) in mice, these nanoparticles change some serum biochemical parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), LDH, and BUN), and pathology of the kidneys indicated that renal injury was induced after exposure [11].
One of the first ultrastructural changes seen after treatment with many nephrotoxins is sloughing of proximal tubule brush borders [12]. The enzymes γ-glutamyltranspeptidase (γ-GTP) and dipeptidylaminopeptidase IV (DAP-IV) are predominantly located on the apical membrane (brush border) of proximal cells [13, 14]. Thus, xenobiotics (in this case TiO2-NPs) can produce release of γ-GTP and DAP-IV from their site in the brush border membrane of renal tubules, causing their urinary excretion (enzymuria). Moreover, along the nephron, the reabsorption and secretion of solutes (sodium and glucose) are done by different cotransporters such as sodium-glucose sodium-phosphate, sodium-amino, Na-K-2Cl, and Na-Cl. Therefore, the damage of the cytoplasmic membrane would disrupt the function of these cotransporters. These transporters are the major participants in urine osmolarity [15].
The Ginkgo biloba extract (GbE) is a commercial product, considered as nutraceutic [16] with possible beneficial effects on human health [17–23]. The GbE contains an average of 27% polyphenols isorhamnetin, kaempferol, and quercetin [24–28] and 6% terpene lactones (terpenoid fraction). The terpenoid fraction primarily contains ginkgolides A, B, C, J, and M, as well as bilobalide. Its purported biological effects include free radical scavenging, antiapoptotic, anti-inflammatory, and antioxidative activities [29]. The GbE is used in many applications such as the treatment of dementia, cerebral insufficiency, or related cognitive decline [30]. The possible mechanisms implied in the neuroprotective effect are modulation of ion homeostasis, glucocorticoid levels, and synthesis of growth factors [31]. In recent clinical and experimental experiments, GbE has been reported to be effective against ischemic brain injury [32, 33], cerebral (or cerebrovascular) insufficiency [34], cognitive speed [35], dementia and Alzheimer’s disease [36], peripheral vascular disease such as arterial occlusive disease [37], and aging damage [38]. In the case of renal cells, the GbE has renoprotective effect against cisplatin-induced nephrotoxicity [29]. In other study, changes in blood urea, serum creatinine, and creatinine clearance induced by gentamicin were significantly prevented by Ginkgo biloba extract [39]. Furthermore, the GbE diminishes adriamycin-induced proteinuria and hyperlipidaemic nephrotoxicity in rats [40].
Our hypothesis was that pretreatment with GbE as a single dose (10 mg/kg of body weight), administered intraperitoneally, would reverse the renal effects of the intravenous administration of a single dose of TiO2-NPs, in the kidneys of adult male rats.
2. Materials and Methods2.1. Animals and Reagents
Male adult Wistar rats (200–300 g) were used and maintained in stainless steel cages with a 12 h light/dark regime. The rats were handled according to the Guiding Principles in the Use of Animals in Toxicology.
Ginkgo biloba extract was from Vasodil®, NYCOMED, México, titanium dioxide nanoparticles were from Anatase, Sigma Aldrich, St. Louis, MO, USA, and γ-glutamyl p-nitroanilide and gly-pro p-nitroanilide were from Sigma Aldrich, St. Louis, MO, USA.
2.2. Experimental Design
Treatment was as follows. The rats were divided into four groups: control group (treated with 5.0 mg/kg of sodium chloride aqueous solution, intravenously or i.v.), titanium dioxide group (5.0 mg/kg of TiO2, i.v.), Ginkgo biloba group (10 mg/kg, intraperitoneal or i.p.), and Ginkgo biloba + titanium dioxide group (treated 24 h before with 10 mg/kg of Ginkgo biloba extract, i.p.), followed, 24 h later, by 5.0 mg/kg of TiO2, i.p.
The rats were kept with food and water ad libitum and at room temperature (24 ± 1°C). The urine was continuously collected, in vessels attached to the metabolic cages, from 0 to 5 h, from 5 to 24 h, from 24 to 48 h, and from 48 to 72 h.
Biochemical assays were as follows. The specific activity of γ-glutamyltranspeptidase was determined in 50 mM Tris-Cl, pH 9.0, 10 mM MgCl2, with 20 mM glycylglycine and γ-glutamyl p-nitroanilide as substrate, in a spectrophotometer at 405 nm [41]. The specific activity of dipeptidylaminopeptidase-IV was assayed in 50 mM Tris-Cl, pH 8.0, with gly-pro p-nitroanilide as substrate, also at 405 nm [42] in a spectrophotometer. The enzymatic activities were carried out at room temperature (25 ± 1°C), in 0.5 mL final incubation volume. The initial enzymatic rates were calculated from continuous recording, usually in duplicates, in a Varian UV/VIS spectrophotometer (Varian DMS 80).
Protein was measured with the Folin phenol reagent using bovine serum albumin as standard [43]. We also measured in urine the volume, the concentration of creatinine [44], the pH in a pH meter, the osmolality in a microosmometer (Osmette, Precision Systems Model 5004), and the concentration of sodium in a flame photometer (Corning M410).
2.3. Statistical Analysis
We calculated the significance of the differences between group means with the two-tailed Student’s t-test for grouped data with ANOVA posttest of the urinary parameters, using the software Prism 4 (GraphPad Software Inc.); graphs were produced using Slide Write Plus version 4.0 for Windows (Advanced Graphics Software Inc.).
3. Results
The pretreatment with a single and intraperitoneal dose of the Ginkgo biloba extract (GbE) reversed the renal effects of a single dose of TiO2-NPs (5 mg/kg, intravenous), studied in the urine of adult male rats.
3.1. The Effects of GbE on the Renal Effects of Titanium Dioxide (TiO2) of the γ-Glutamyltranspeptidase Enzymatic Activity in Urine
The increased enzymatic activity of γ-glutamyltranspeptidase, generated by titanium dioxide, was totally and significantly (P<0.05) reversed with the 24 h pretreatment of GbE, from 64.4±10.7 to 6.9±0.8 (0–5 h), from 63.3±9.6 to 14.5±0.5 (5–24 h), from 40.9±0.6 to 5.8±0.9 (24–48 h), and from 48.3±3.4 to 4.5±0.2 nmol pNA/min × mg of protein (48–72 h), as shown in Figure 1.
The effects of GbE on the renal effects of titanium dioxide (TiO2) of the γ-glutamyltranspeptidase enzymatic activity in urine, at different time periods, compared with control, GbE, and TiO2-treated rats. The enzymatic activity is shown as nmol p-NA/min × mg of protein. The values represent mean ± SEM, n=6. The significance level is P∗∗<0.01; pNA: p-nitroanilide.
3.2. The Effects of GbE on the Renal Effects of Titanium Dioxide on the Enzymatic Activity of Urinary Dipeptidylaminopeptidase IV
The GbE partially and significantly (P<0.05) reversed the increase on enzymatic activity of dipeptidylaminopeptidase IV, produced by TiO2, from 11.1±0.9 to 4.0±0.3 (0–5 h), from 9.8±0.5 to 6.7±0.7 (5–24 h), from 8.1±0.7 to 2.8±0.1 (24–48 h), and from 8.5±0.3 to 2.1±0.1 nmol pNA/min × mg of protein (48–72 h), as depicted in Figure 2.
The effects of GbE on the renal effects of titanium dioxide on the enzymatic activity of urinary dipeptidylaminopeptidase IV, at different time periods, compared with control, GbE, and TiO2-treated rats. The enzymatic activity is shown as nmol p-NA/min × mg of protein. The values represent mean ± SEM, n=6. The significance level is P∗∗<0.01; pNA: p-nitroanilide.
3.3. The Effects of GbE on the Renal Effects of TiO2 of the Glucose Concentration in Urine
Figure 3 shows that the GbE decreased significantly (P<0.05) the glucosuria, produced by titanium dioxide, only at 5 to 24 h (29.2±3.2 to 2.5±0.2), and again from 48 to 72 h (19.1±3.5 to 4.8±0.6 mg/dL). The values from 24 to 48 h were not significantly different that control or GbE-treated rats.
The effects of GbE on the renal effects of TiO2 of the glucose concentration in urine, at different time periods, compared with control, GbE, and TiO2-treated rats. The glucose concentration is presented as mg/dL. The significance level is P∗∗<0.01.
3.4. The Effects of GbE on the Renal Effects of TiO2 of the Urinary Sodium Concentration
In Figure 4 it is shown that the GbE decreased significantly (P<0.05) the hypernatruria produced by titanium dioxide: from 5 to 24 h (85±17 to 49±9), from 24 to 48 h (104±9 to 63±5), and from 48 to 72 h (126±8 to 73±5 mEq/L).
The effects of GbE on the renal effects of TiO2 of the urinary sodium concentration, at different time periods, compared with control, GbE, and TiO2-treated rats. The sodium concentration is presented as mEquivalents of Na+/liter. The significance levels are: P∗<0.05, P∗∗<0.01.
3.5. The Effects of GbE on the Renal Effects of Titanium Dioxide in the Urine Osmolarity
The GbE diminished significantly (P<0.05) the urinary hyperosmolarity produced by TiO2 only from 5–24 h (580±19 to 272±69) and again from 48 to 72 h (516±7 to 357±20 mOsmol/L), as depicted in Figure 5. The values from 24 to 48 h were not significantly different that control or GbE-treated rats.
The effects of GbE on the renal effects of titanium dioxide in the urine osmolarity, at different time periods, compared with control, GbE, and TiO2-treated rats. The osmolarity is shown as mOsmoles/liter. The significance level is P∗∗<0.01.
3.6. The Effects of GbE and Titanium Dioxide on Other Urinary Parameters
Finally, the GbE alone did not significantly modify the concentrations of protein and creatinine, the volume, or the pH of urine, respectively, compared to control or GbE-pretreated rats, as shown in Table 1. Likewise, the GbE did not significantly modify the water and food intakes or the body weight, respectively, also compared to control or GbE-pretreated rats, as depicted in Table 2.
The effects of the Ginkgo biloba extract (10 mg/kg b.w., intraperitoneal) administered 24 h before titanium dioxide (5 mg/kg b.w., intravenous) on other urinary parameters studied.
Parameter
0–5 h
5–24 h
24–48 h
48–72 h
Protein (mg/mL)
Control
4.5 ± 0.3
8.8 ± 0.4
8.2 ± 0.2
8.8 ± 0.2
Control Gb
6.8 ± 2.2
7.5 ± 1.8
10.7 ± 0.8
8.2 ± 0.8
Treated TiO2
5.3 ± 0.5
5.6 ± 0.3
6.9 ± 0.3
7.8 ± 0.1
Pretreated Gb
6.9 ± 0.3
6.6 ± 1.5
8.3 ± 0.2
7.3 ± 0.2
Total creatinine (mg/dL)
Control
57 ± 2.1
87 ± 1.7
77 ± 2.7
62 ± 5.1
Control Gb
46 ± 6.9
67 ± 12.8
68 ± 1.9
55 ± 3.9
Treated TiO2
47 ± 1.5
77 ± 1.3
83 ± 0.6
84 ± 6.5
Pretreated Gb
47 ± 7.9
56 ± 6.3
63 ± 2.2
50 ± 1.7
Volume (mL)
Control
4.0 ± 0.5
8.7 ± 0.7
8.7 ± 0.5
13.7 ± 1.4
Control Gb
2.5 ± 0.2
8.0 ± 2
7.0 ± 1.3
7.0 ± 0.9
Treated TiO2
3.0 ± 0.15
9.0 ± 1.0
9.0 ± 1.0
9.0 ± 1.0
Pretreated Gb
2.6 ± 0.2
10 ± 2
10 ± 1
11 ± 1
pH
Control
7.6 ± 0.2
7.4 ± 0.3
7.3 ± 0.3
6.9 ± 0.4
Control Gb
8.0 ± 0.05
7.0 ± 0.5
6.5 ± 0.2
7.8 ± 0.1
Treated TiO2
6.5 ± 0.3
6.5 ± 0.3
6.8 ± 0.2
6.3 ± 0.2
Pretreated Gb
7.0 ± 0.3
7.8 ± 0.2
7.8 ± 0.2
7.7 ± 0.2
Values represent mean ± SEM (n=6).
The effects of the Ginkgo biloba extract (10 mg/kg b.w., intraperitoneal) administered 24 h before titanium dioxide (5 mg/kg b.w., intravenous) on general parameters studied.
Parameter
5–24 h
24–48 h
48–72 h
Water consumption (mL in 19 or 24 h)
Control
35 ± 3.4
32 ± 3.1
35 ± 1.9
Control Gb
23 ± 5.0
42 ± 7.2
32 ± 5.2
Treated TiO2
35 ± 5.1
32 ± 4.1
30 ± 4.1
Pretreated Gb
25 ± 3.3
38 ± 2.4
33 ± 2.2
Food consumption (g in 19 or 24 h)
Control
18 ± 1.3
19 ± 0.7
21 ± 1.4
Control Gb
14 ± 1.5
14 ± 5.1
12 ± 4.1
Treated TiO2
19 ± 1.1
16 ± 1.3
15 ± 1.4
Pretreated Gb
18 ± 1.2
17 ± 1.4
17 ± 1.2
Body weight (g in 19 or 24 h)
Control
305 ± 10
302 ± 10
299 ± 11
Control Gb
282 ± 24
280 ± 18
269 ± 23
Treated TiO2
227 ± 13
237 ± 14
246 ± 16
Pretreated Gb
278 ± 13
270 ± 16
273 ± 33
Values represent mean ± SEM (n=6).
In Figure 6, we show a scheme about the possible mechanisms of the GbE polyphenols to protect the cytoplasmic membrane from renal effects produced by the titanium dioxide nanoparticles, at the luminal side of the brush border cells, all along the renal tubules of rat kidneys.
Scheme on the possible mechanisms of the GbE polyphenols for the renoprotection of the cytoplasmic membrane against the effects generated by the TiO2 nanoparticles, at the luminal side of the brush border cells, along the renal tubules of rat kidneys. γGT: γ-glutamyltranspeptidase, DAP-IV: dipeptidylaminopeptidase IV, CoT: electroneutral Na-K-Cl cotransporter, and Gluc T2: Glucose-Na cotransporter 2.
4. Discussion
The administration of a single and intraperitoneal dose of the Ginkgo biloba extract (GbE, 10 mg/kg of body weight) significantly (>0.05) reversed the renal effects of a single and intravenous dose (5 mg/kg) of titanium dioxide (TiO2) nanoparticles, studied in the urine of adult male rats. The dose of TiO2 that we used is 11.8 times lower than its LD50 [45]. TiO2-NPs are a fine white powder, often used as pigments or additives for ceramics, paints, paper, plastics, food, sunscreens, and toothpaste [46]. Living organisms are exposed to TiO2-NPs and may develop toxic effects. The toxicity of TiO2-NPs has mainly been studied in vitro [47–50] but with fewer studies in vivo [51] and a growing need for in vivo research on the effects of nanoparticles [52, 53].
Ginkgo biloba is one of the most widely used herbal remedies in Europe and US [54]. It is well known that the GbE contains 27% of the polyphenols isorhamnetin, kaempferol, and quercetin [24–27].
We believe that the renoprotective effects of the GbE, against the effects of TiO2 nanoparticles, are mainly due to the higher content and the interaction of the three GbE polyphenols with the cytoplasmic membrane of the brush border cells on the renal tubules and perhaps also to a synergistic effect among them.
The polyphenols interact with model membranes [55–67] and with erythrocyte membranes [68–70]. Some of the previous authors report evidence that this interaction is mainly due to hydrogen bonding between lipid polar head groups of membranes and the hydroxyl groups of polyphenols. This interaction would stabilize the membranes and influence their fluidity by decreasing packing in the hydrophilic region of membrane.
In relation to the specific activity of γ-glutamyltranspeptidase (γ-GTP) and dipeptidylaminopeptidase IV (DAP-IV), because they are in contact with the lumen of the renal tubules, and due to their location in the brush border membrane of renal proximal tubules [13, 14], they are the most susceptible parameters to the direct adverse effect by TiO2-NPs, and thus, they are the most benefited by the GbE at all times tested. This can be explained because the polyphenols exert a screen effect combined with its chelating and antioxidant activity. These properties have been well studied in quercetin [71, 72].
According to the other parameters, the time-related effects of TiO2-NPs were detected after the enzymuria, as increased concentration of the urinary glucose (glucosuria) and increased concentration of the urinary sodium (hypernatriuria), along with increased of urine osmolality. Similarly, with its polyphenols, the GbE exerted its beneficial mentioned properties [71, 72], protecting and preventing a dysregulation in the function of nephron cotransporters involved in the regulation of sodium, glucose, and therefore the osmolarity, produced by the TiO2-NPs.
Likewise, it is possible that the GbE renoprotection is potentiated by its components as reported in vivo for their pharmacokinetics in rats [73] and for the treatment of cancer [74–76]. We also believe that the polyphenols of the GbE participate, as antioxidants [77], in the renoprotective effects against TiO2, mainly at later times [78].
We do not rule out the participation of the antioxidant effects of GbE components on the renal effects like oxidative stress, generated by nanoparticles, reported by several authors [55, 79–82].
Finally, we could not find significant differences among the control, the GbE, and the TiO2-treated rats for the following urinary parameters: the volume, the concentration of protein, the concentration of creatinine, or the pH. Likewise, the water and food intakes as well as the gain in body weight were not statistically different in control rats, compared with the GbE, and the TiO2-treated rats.
5. Conclusions
The administration of Ginkgo biloba extract (GbE, 10 mg/kg of body weight) by the intraperitoneal route and as a single dose reversed the renal effects of a single and intravenous dose (5 mg/kg) of titanium dioxide (TiO2) nanoparticles in male and adult rats, studied in the urine. The GbE recovered the enzymatic activities of γ-glutamyltranspeptidase and of dipeptidylaminopeptidase IV. The GbE also reversed the glucosuria, the hypernatruria, and the hyperosmolarity generated by titanium dioxide. These effects appear to be mainly due to the interaction and protection of the GbE polyphenols with the cytoplasmic membrane on renal tubules of the male adult rats. Thus, we conclude that GbE has a beneficial activity in the cytoplasmic membranes of brush border cells on the renal tubules, against the adverse effects that can be produced by some xenobiotics, in this case the TiO2-NPs, in experimental rats. Therefore, our research highlights the pharmacological activity of the Ginkgo biloba extract, which can be used as an alternative treatment to protect renal cells against the toxicity produced by TiO2-NPs.
Conflict of Interests
The authors acknowledge that there is no conflict of interests.
Acknowledgments
The authors acknowledge the doctoral fellowship to Carlos Enrique Escárcega-González (CONACYT-CVU: 377051) and the research funding for their Academic Group from PROMEP-SEP (UAA CA25) to the Universidad Autónoma de Aguascalientes.
GiebishG.WindhagerE.BoronW. F.BoulpaepE. L.Organization of the urinary system2008Philadelphia, Pa, USASaunders, Elsevier Science747766FengW.WangB.ZhaoY.SahuS. C.CascianoD. A.Nanotoxicity of metal oxide nanoparticles in vivo2009chapter 13Chichester, UKJohn Wiley & Sons24726910.1002/9780470747803.ch13ShiH.MagayeR.CastranovaV.ZhaoJ.Titanium dioxide nanoparticles: a review of current toxicological data2013101, article 1510.1186/1743-8977-10-152-s2.0-84876113687ShvedovaA. A.KaganV. E.FadeelB.Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems201050638810.1146/annurev.pharmtox.010909.1058192-s2.0-71949102618BarilletS.Simon-DeckersA.Herlin-BoimeN.Mayne-L'HermiteM.ReynaudC.CassioD.GougetB.CarrièreM.Toxicological consequences of TiO2, SiC nanoparticles and multi-walled carbon nanotubes exposure in several mammalian cell types: an in vitro study2010121617310.1007/s11051-009-9694-y2-s2.0-75049083102L'AzouB.JorlyJ.OnD.SellierE.MoisanF.Fleury-FeithJ.CambarJ.BrochardP.Ohayon-CourtèsC.In vitro effects of nanoparticles on renal cells20085, article 2210.1186/1743-8977-5-222-s2.0-58249141684PujaltéI.PassagneI.BrouillaudB.TréguerM.DurandE.Ohayon-CourtèsC.L'AzouB.Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human kidney cells20118, article 1010.1186/1743-8977-8-102-s2.0-79952107710ŠebekováK.DušinskáM.Simon KlenovicsK.KollárováR.BoorP.KebisA.StaruchováM.VlkováB.CelecP.HodosyJ.BačiakL.TuškováR.BeňoM.TulinskáJ.PríbojováJ.BilaničováD.PojanaG.MarcominiA.VolkovováK.Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats20148214215710.3109/17435390.2012.7631472-s2.0-84890390346ShiH.MagayeR.CastranovaV.ZhaoJ.Titanium dioxide nanoparticles: a review of current toxicological data201310, article 1510.1186/1743-8977-10-152-s2.0-84876113687FabianE.LandsiedelR.Ma-HockL.WienchK.WohllebenW.van RavenzwaayB.Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats200882315115710.1007/s00204-007-0253-yWangJ.ZhouG.ChenC.YuH.WangT.MaY.JiaG.GaoY.LiB.SunJ.LiY.JiaoF.ZhaoY.ChaiZ.Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration2007168217618510.1016/j.toxlet.2006.12.0012-s2.0-33846131928StrooW. E.HookJ. B.Enzymes of renal origin in urine as indicators of nephrotoxicity197739342343410.1016/0041-008X(77)90135-12-s2.0-0017398285GuderW. G.RossB. D.Enzyme distribution along the nephron198426210111110.1038/ki.1984.1432-s2.0-0021619876KennyA. J.BoothA. G.GeorgeS. G.IngramJ.KershawD.WoodE. J.YoungA. R.Dipeptidyl peptidase IV, a kidney brush-border serine peptidase1976157116918210.1042/bj1570169ChoiH.-J.YoonY.-J.KwonY.-K.LeeY.-J.ChaeS.HwangD.HwangG.-S.KwonT.-H.Patterns of gene and metabolite define the effects of extracellular osmolality on kidney collecting duct20121173816382810.1021/pr300309d2-s2.0-84863620828BeerA. M.Herbal medicines used in kidney diseases in Europe20115282852-s2.0-79958756578BrinkleyT. E.LovatoJ. F.ArnoldA. M.FurbergC. D.KullerL. H.BurkeG. L.NahinR. L.LopezO. L.YasarS.WilliamsonJ. D.Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women201023552853310.1038/ajh.2010.142-s2.0-77951122669ChanP.-C.XiaQ.FuP. P.Ginkgo biloba leave extract: biological, medicinal, and toxicological effects200725321124410.1080/105905007015694142-s2.0-34548321002CulmseeC.KrieglsteinJ.Ischaemic brain damage after stroke: new insights into efficient therapeutic strategies. International Symposium on Neurodegeneration and Neuroprotection20078212913310.1038/sj.embor.74008922-s2.0-33947288475FransenH. P.PelgromS. M. G. J.Stewart-KnoxB.de KasteD.VerhagenH.Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba201054, article 52212-s2.0-79251505591MahadevanS.ParkY.Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses2008731R14R1910.1111/j.1750-3841.2007.00597.x2-s2.0-38349102172PontoL. L.SchultzS. K.Ginkgo biloba extract: review of CNS effects200315210911910.1023/a:10246883260232-s2.0-0345871329ZhangY.WangX.WangL.YuM.HanX.Interactions of the baicalin and baicalein with bilayer lipid membranes investigated by cyclic voltammetry and UV-Vis spectroscopy201495293310.1016/j.bioelechem.2013.10.0082-s2.0-84887714733DengF.ZitoS. W.Development and validation of a gas chromatographic-mass spectrometric method for simultaneous identification and quantification of marker compounds including bilobalide, ginkgolides and flavonoids in Ginkgo biloba L. extract and pharmaceutical preparations2003986112112710.1016/s0021-9673(02)01921-02-s2.0-0037473927DubberM.-J.KanferI.High-performance liquid chromatographic determination of selected flavonols in Ginkgo biloba solid oral dosage forms2004733033092-s2.0-27444443147LiC.-Y.LinC.-H.WuC.-C.LeeK.-H.WuT.-S.Efficient 1H nuclear magnetic resonance method for improved quality control analyses of Ginkgo constituents200452123721372510.1021/jf049920h2-s2.0-2942588524van BeekT. A.MontoroP.Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals20091216112002203210.1016/j.chroma.2009.01.0132-s2.0-60349092143YaoX.ZhouG.-S.TangY.-P.QianY.-F.GuanH.-L.PangH.ZhuS.MoX.SuS.-L.JinC.QinY.QianD.-W.DuanJ.-A.Simultaneous quantification of flavonol glycosides, terpene lactones, biflavones, proanthocyanidins, and ginkgolic acids in ginkgo biloba leaves from fruit cultivars by ultrahigh-performance liquid chromatography coupled with triple quadrupole mass spectrometry201320131158259110.1155/2013/5825912-s2.0-84874620197SongJ.LiuD.FengL.ZhangZ.JiaX.XiaoW.Protective effect of standardized extract of Ginkgo biloba against cisplatin-induced nephrotoxicity201320131184612610.1155/2013/8461262-s2.0-84893748213ChenW.-D.LiangY.XieL.LuT.LiuX.-D.WangG.-J.Pharmacokintics of the Ginkgo Bfollowing intravenous administration of Ginkgo B emulsion in rats20073011510.1248/bpb.30.12-s2.0-33846046086CárdenasJ. M.MartínezM. C.JaramilloF.RodríguezM. L.GutiérrezF. J.PosadasF. A.AvelarF. J.GuerreroA. L.The protective effect of Ginkgo biloba on the damage induced by methyl parathion in cerebellar granule cells of rat20104143742KleijnenJ.KnipschildP.Ginkgo biloba for cerebral insufficiency199234435235810.1111/j.1365-2125.1992.tb05642.x2-s2.0-0026793093ZhangW. R.HayashiT.KitagawaH.SasakiC.SakaiK.WaritaH.WangJ. M.ShiroY.UchidaM.AbeK.Protective effect of Ginkgo extract on rat brain with transient middle cerebral artery occlusion20002255175212-s2.0-0033853197VesperJ.HänsgenK. D.Efficacy of Ginkgo biloba in 90 outpatients with cerebral insufficiency caused by old age: results of a placebo-controlled double-blind trial19941191610.1016/s0944-7113(11)80017-6KennedyD. O.ScholeyA. B.WesnesK. A.The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers2000151441642310.1007/s0021300005012-s2.0-0033829312Le BarsP. L.KatzM. M.BermanN.ItilT. M.FreedmanA. M.SchatzbergA. F.A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia1997278161327133210.1001/jama.1997.035501600470372-s2.0-0030759072PetersH.KieserM.HölscherU.Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication—a placebo-controlled, double-blind multicenter trial1998272106110DiamondB. J.ShiflettS. C.FeiwelN.MatheisR. J.NoskinO.RichardsJ. A.SchoenbergerN. E.Ginkgo biloba extract: mechanisms and clinical indications200081566867810.1053/mr.2000.38402-s2.0-0034094018NaiduM. U. R.ShifowA. A.KumarK. V.RatnakarK. S.Ginkgo biloba extract ameliorates gentamicin-induced nephrotoxicity in rats20007319119710.1016/s0944-7113(00)80003-32-s2.0-0034094183Abd-EllahM. F.MarieeA. D.Ginkgo biloba leaf extract (EGb 761) diminishes adriamycin-induced hyperlipidaemic nephrotoxicity in rats: association with nitric oxide production2007461354010.1042/ba200600852-s2.0-33846317126OrlowskiM.MeisterA.γ-Glutamyl-p-nitroanilide: a new convenient substrate for determination of L- and D-γ-glutamyltranspeptidase activities196373679681YoshimotoT.FischlM.OrlowskiR. C.WalterR.Post-proline cleaving enzyme and post-proline dipeptidyl aminopeptidase. Comparison of two peptidases with high specificity for proline residues197825310370837162-s2.0-0017893194JaffeM.Ueber den niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue reaction des Kreatinins188610539140010.1515/bchm1.1886.10.5.391LowryO. H.RosenbroughN. J.FarrA. L.RandallR. J.Protein measurement with the Folin phenol reagent195119312652752-s2.0-71849104860VolkovovaK.HandyR. D.StaruchovaM.Health effects of selected nanoparticles in vivo: liver function and hepatotoxicity following intravenous injection of titanium dioxide and Na-oleate-coated iron oxide nanoparticles in rodents20159supplement 19510510.3109/17435390.2013.815285ChenX.MaoS. S.Titanium dioxide nanomaterials: synthesis, properties, modifications and applications200710772891295910.1021/cr05005352-s2.0-34547486889AroraS.RajwadeJ. M.PaknikarK. M.Nanotoxicology and in vitro studies: the need of the hour2012258215116510.1016/j.taap.2011.11.0102-s2.0-84855785145IavicoliI.LesoV.FontanaL.BergamaschiA.Toxicological effects of titanium dioxide nanoparticles: a review of in vitro mammalian studies20111554815082-s2.0-79960984721JinC.TangY.YangF. G.LiX. L.XuS.FanX. Y.HuangY. Y.YangY. J.Cellular toxicity of TiO2 nanoparticles in anatase and rutile crystal phase20111411–331510.1007/s12011-010-8707-02-s2.0-79959609859SmuldersS.LuytsK.BrabantsG.GolanskiL.MartensJ.VanoirbeekJ.HoetP. H. M.Toxicity of nanoparticles embedded in paints compared to pristine nanoparticles, in vitro study2015232233333910.1016/j.toxlet.2014.11.0302-s2.0-84919782455SmuldersS.LuytsK.BrabantsG.Van LanduytK.KirschhockC.SmoldersE.GolanskiL.VanoirbeekJ.HoetP. H. M.Toxicity of nanoparticles embedded in paints compared with pristine nanoparticles in mice2014141113214010.1093/toxsci/kfu1122-s2.0-84913613623FischerH. C.ChanW. C.Nanotoxicity: the growing need for in vivo study200718656557110.1016/j.copbio.2007.11.0082-s2.0-37549042771IavicoliI.LesoV.BergamaschiA.Toxicological effects of titanium dioxide nanoparticles: a review of in vivo studies201220123696438110.1155/2012/9643812-s2.0-84862277870AroraA.ByremT. M.NairM. G.StrasburgG. M.Modulation of liposomal membrane fluidity by flavonoids and isoflavonoids2000373110210910.1006/abbi.1999.15252-s2.0-0033972299HeinonenT.GausW.Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgo biloba leaf extract201532719511510.1016/j.tox.2014.10.0132-s2.0-84916624177Cieślik-BoczulaK.ManiewskaJ.GrynkiewiczG.SzejaW.KollA.HendrichA. B.Interaction of quercetin, genistein and its derivatives with lipid bilayers—an ATR IR-spectroscopic study201262646910.1016/j.vibspec.2012.05.0102-s2.0-84865622102HendrichA. B.Flavonoid-membrane interactions: possible consequences for biological effects of some polyphenolic compounds2006271274010.1111/j.1745-7254.2006.00238.x2-s2.0-30144442832IngólfssonH. I.ThakurP.HeroldK. F.HobartE. A.RamseyN. B.PerioleX.De JongD. H.ZwamaM.YilmazD.HallK.MaretzkyT.HemmingsH. C.BlobelC.MarrinkS. J.KoçerA.SackJ. T.AndersenO. S.Phytochemicals perturb membranes and promiscuously alter protein function2014981788179810.1021/cb500086e2-s2.0-84906252868LehtonenJ. Y. A.AdlercreutzH.KinnunenP. K. J.Binding of daidzein to liposomes1996128519110010.1016/s0005-2736(96)00154-x2-s2.0-0030582569LiaoK.-L.YinM.-C.Individual and combined antioxidant effects of seven phenolic agents in human erythrocyte membrane ghosts and phosphatidylcholine liposome systems: importance of the partition coefficient20004862266227010.1021/jf990946w2-s2.0-0033918336OllilaF.HallingK.VuorelaP.VuorelaH.SlotteJ. P.Characterization of flavonoid-biomembrane interactions2002399110310810.1006/abbi.2001.27592-s2.0-0036509466OteizaP. I.ErlejmanA. G.VerstraetenS. V.KeenC. L.FragaC. G.Flavonoid-membrane interactions: a protective role of flavonoids at the membrane surface?2005121192510.1080/104466704100017221682-s2.0-18444383384Pawlikowska-PawlegaB.MisiakL. E.ZarzykaB.PaduchR.GawronA.GruszeckiW. I.Pawlikowska-PawlęgaB.Modification of membranes by quercetin, a naturally occurring flavonoid, via its incorporation in the polar head group20071768921952204Pawlikowska-PawlęgaB.MisiakL. E.ZarzykaB.PaduchR.GawronA.GruszeckiW. I.Localization and interaction of genistein with model membranes formed with dipalmitoylphosphatidylcholine (DPPC)2012181871785179310.1016/j.bbamem.2012.03.0202-s2.0-84860114663RaghunathanM.ZubovskiY.VenableR. M.PastorR. W.NagleJ. F.Tristram-NagleS.Structure and elasticity of lipid membranes with genistein and daidzein bioflavinoids using X-ray scattering and MD simulations2012116133918392710.1021/jp211904j2-s2.0-84859608897ScheidtH. A.PampelA.NisslerL.GebhardtR.HusterD.Investigation of the membrane localization and distribution of flavonoids by high-resolution magic angle spinning NMR spectroscopy200416631-29710710.1016/j.bbamem.2004.02.0042-s2.0-2442479970TsuchiyaH.NagayamaM.TanakaT.FurusawaM.KashimataM.TakeuchiH.Membrane-rigidifying effects of anti-cancer dietary factors2002163-4455610.1002/biof.55201603012-s2.0-0141957272AjdžanovićV.SpasojevićI.FilipovićB.Šošić-JurjevićB.SekulićM.MiloševicV.Effects of genistein and daidzein on erythrocyte membrane fluidity: an electron paramagnetic resonance study201088449750010.1139/y10-0202-s2.0-77952068968CyboranS.OszmiańskiJ.KleszczyńskaH.Interaction between plant polyphenols and the erythrocyte membrane2012171778810.2478/s11658-011-0038-42-s2.0-84859513130Pawlikowska-PawlęgaB.GruszeckiW. I.MisiakL. E.GawronA.The study of the quercetin action on human erythrocyte membranes200366460561210.1016/s0006-2952(03)00344-72-s2.0-0142039144FiorucciS.GolebiowskiJ.Cabrol-BassD.AntonczakS.DFT study of quercetin activated forms involved in antiradical, antioxidant, and prooxidant biological processes200755390391110.1021/jf061864s2-s2.0-34247894012PaulíkováH.BerczeliováE.The effect of quercetin and galangin on glutathione reductase2005149249750010.5507/bp.2005.0892-s2.0-36049010952GuanH.QianD.RenH.ZhangW.NieH.ShangE.DuanJ.Interactions of pharmacokinetic profile of different parts from Ginkgo biloba extract in rats2014155175876810.1016/j.jep.2014.06.0222-s2.0-84904996070LiuR. H.Potential synergy of phytochemicals in cancer prevention: mechanism of action2004134123479S3485S2-s2.0-9744222928YangY.ZhangZ.LiS.YeX.LiX.HeK.Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis201492213314710.1016/j.fitote.2013.10.0102-s2.0-84889063414WagnerH.Synergy research: approaching a new generation of phytopharmaceuticals2011821343710.1016/j.fitote.2010.11.0162-s2.0-79151482960PahariB.ChakrabortyS.ChaudhuriS.SenguptaB.SenguptaP. K.Binding and antioxidant properties of therapeutically important plant flavonoids in biomembranes: insights from spectroscopic and quantum chemical studies2012165448849610.1016/j.chemphyslip.2011.10.0062-s2.0-84860757596Escárcega-GonzálezC. E.2012Aguascalientes, MéxicoDepartamento de Farmacología y Fisiología y Departamento de Departamento de Química. Centro de Ciencias Básicas, Universidad Autónoma de AguascalientesBoltH. M.MarchanR.HengstlerJ. G.Nanotoxicology and oxidative stress control: cutting-edge topics in toxicology201286111629163510.1007/s00204-012-0953-92-s2.0-84871242194BrunoM. E.TasatD. R.RamosE.PaparellaM. L.EvelsonP.RebagliatiR. J.CabriniR. L.GuglielmottiM. B.OlmedoD. G.Impact through time of different sized titanium dioxide particles on biochemical and histopathological parameters201410251439144810.1002/jbm.a.348222-s2.0-84897114081Halamoda KenzaouiB.Chapuis BernasconiC.Juillerat-JeanneretL.Stress reaction of kidney epithelial cells to inorganic solid-core nanoparticles2013291395810.1007/s10565-012-9236-82-s2.0-84872355246HussainS.BolandS.Baeza-SquibanA.HamelR.ThomassenL. C. J.MartensJ. A.Billon-GallandM. A.Fleury-FeithJ.MoisanF.PaironJ.-C.MaranoF.Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount20092601–314214910.1016/j.tox.2009.04.0012-s2.0-65649127246